Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD

Migration, Crosslink

📖

Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-aso-c9orf72-als

📖 Wiki Page

therapeutic1606 wordssynced 2026-04-02

Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Antisense oligonucleotide (ASO) therapy targeting [C9orf72](/genes/c9orf72) represents one of the most promising disease-modifying approaches for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by hexanucleotide repeat expansions. This therapeutic strategy aims to reduce the levels of toxic dipeptide repeat proteins (DPRs) generated by aberrant translation of the expanded GGGGCC repeat in the [C9orf72](/entities/c9orf72) gene. [@zhang2019]

C9orf72 repeat expansions are the most common genetic cause of familial ALS and FTD, accounting for approximately 40% of familial ALS cases and 25% of familial FTD cases. The development of ASO therapies specifically targeting this mutation represents a precision medicine approach to neurodegenerative disease treatment. [@krach2018]

Mechanism of Action

Hexanucleotide Repeat Expansion Pathogenesis

...

Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Antisense oligonucleotide (ASO) therapy targeting [C9orf72](/genes/c9orf72) represents one of the most promising disease-modifying approaches for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by hexanucleotide repeat expansions. This therapeutic strategy aims to reduce the levels of toxic dipeptide repeat proteins (DPRs) generated by aberrant translation of the expanded GGGGCC repeat in the [C9orf72](/entities/c9orf72) gene. [@zhang2019]

C9orf72 repeat expansions are the most common genetic cause of familial ALS and FTD, accounting for approximately 40% of familial ALS cases and 25% of familial FTD cases. The development of ASO therapies specifically targeting this mutation represents a precision medicine approach to neurodegenerative disease treatment. [@krach2018]

Mechanism of Action

Hexanucleotide Repeat Expansion Pathogenesis

The C9orf72 gene contains a polymorphic hexanucleotide repeat expansion (GGGGCC) in its first intron that can expand from the normal 2-30 repeats to hundreds or even thousands of repeats in affected individuals. This expansion leads to disease through three primary mechanisms: [@peters2015]

RNA Toxicity: The expanded repeat RNA forms nuclear RNA foci that sequester essential RNA-binding proteins, including hnRNPs (heterogeneous nuclear ribonucleoproteins), disrupting normal RNA processing and splicing.

Dipeptide Repeat Protein (DPR) Toxicity: Aberrant translation of the expanded repeat in all three reading frames produces five distinct DPRs: poly-GA, poly-GP, poly-GR, poly-PA, and poly-PR. These aggregating proteins cause proteostasis disruption, nucleocytoplasmic transport defects, and mitochondrial dysfunction.

Loss of Function: The expansion reduces C9orf72 mRNA expression through epigenetic silencing, potentially disrupting normal lysosomal and autophagic functions in [neurons](/entities/neurons) and glial cells.

ASO Design and Target Selection

ASOs are short, single-stranded oligonucleotides (typically 12-25 nucleotides) that bind to complementary target RNA via Watson-Crick base pairing. For C9orf72 ASO therapy, the primary targets include: [@mori2013]

Repeat-Containing RNA: ASOs can be designed to bind specifically to the expanded repeat RNA, preventing the formation of toxic RNA foci and blocking aberrant DPR translation through a mechanism called repeat-associated non-AUG (RAN) translation.
Splice-Modifying ASOs: Alternative approaches target the C9orf72 pre-mRNA to modulate splicing, potentially increasing the expression of the more functional C9orf72 isoform or reducing toxic transcript variants.

The most advanced ASO candidates target the repeat RNA to suppress DPR production while preserving as much normal C9orf72 function as possible. [@gendron2017]

Pharmacodynamics

Upon binding to target RNA, ASOs exert their effects through two primary mechanisms: [@jiang2016]

RNase H1-Mediated Degradation: Gapmer ASOs contain a central DNA-like region that recruits RNase H1, an endonuclease that cleaves the RNA strand in DNA-RNA hybrids, leading to target RNA degradation.

Steric Blockade: Steric-blocking ASOs (non-gapmer) bind to target RNA without recruiting RNase H, instead blocking translation initiation, ribosomal assembly, or splice site recognition without degrading the target.

Preclinical Evidence

iPSC Models

Patient-derived induced pluripotent stem cell (iPSC) models have been instrumental in validating ASO therapy for C9orf72 ALS/FTD: [@donnelly2013]

RNA Foci Reduction: Studies have demonstrated that ASO treatment effectively reduces C9orf72 RNA foci in patient-derived motor neurons and cortical neurons. This reduction correlates with decreased sequestration of RNA-binding proteins like hnRNPA1 and SRSF2. [@lagiertourenne2013]

Dipeptide Repeat Protein Suppression: Multiple studies have shown that ASO treatment significantly reduces DPR protein levels in iPSC-derived neurons. For example, ASOs targeting the repeat region reduce poly-GA, poly-GR, and poly-PR levels by 60-90% depending on the cell model and ASO design. [@zheng2023]

Rescue of Cellular Phenotypes: Beyond reducing toxic species, ASO treatment has been shown to rescue several disease-relevant cellular phenotypes: [@bristol2022]

Improved neuronal survival
Reduced nucleocytoplasmic transport defects
Decreased mitochondrial dysfunction
Normalization of synaptic markers
Restoration of autophagic flux

Animal Models

Transgenic mouse models expressing the human C9orf72 repeat expansion have provided critical in vivo validation: [@liu2021]

C9BAC transgenic mice: Show age-dependent motor dysfunction, RNA foci, DPR inclusions, and gliosis similar to human disease
C9orf72 knock-in mice: Model with endogenous expression of the human repeat expansion

ASO delivery in these models demonstrates: [@cheng2020]

Efficient knockdown of C9orf72 RNA in CNS tissues
Reduction of RNA foci and DPR aggregates
Improved motor performance in some studies
Good tolerability at therapeutic doses

Clinical Trials

Biogen/Bristol Myers Squibb ASO Program

The most advanced C9orf72 ASO program has been developed through collaboration between Biogen and Bristol Myers Squibb: [@rohrer2015]

BIIB078 (formerly BMS-986369): This ASO targets the C9orf72 repeat expansion and has undergone clinical evaluation: [@van2015]

Phase 1 Study: Completed first-in-human study in healthy volunteers and C9orf72 carriers to evaluate safety, tolerability, and pharmacokinetics
Phase 1/2 Study: Evaluated in patients with C9orf72-associated ALS

The clinical trials have investigated multiple dose levels administered via intrathecal injection to achieve direct CNS delivery. [@baloh2017]

Other Programs

Additional ASO programs targeting C9orf72 have been advanced by other pharmaceutical companies and academic groups, though Biogen's program remains the most clinically advanced. [@gitler2016]

Clinical Outcomes

While full clinical trial results continue to emerge, early data indicate:

Safety: Generally well-tolerated with manageable adverse events
Target Engagement: Evidence of dose-dependent reduction of C9orf72 repeat RNA in cerebrospinal fluid
Biomarkers: DPR levels in CSF being evaluated as potential pharmacodynamic markers

Safety Profile

Observed Adverse Events

Clinical trial data to date have identified several categories of adverse events:

Common (≥10%):

Headache
Back pain
Procedural pain (related to intrathecal delivery)

Injection-Related:

Post-lumbar puncture syndrome
CSF leakage
Rare meningitis concerns

Potential Neurological:

Transient sensory symptoms
Careful monitoring for neuroinflammation

Risk Mitigation

The safety profile supports continued development, with risk mitigation strategies including:

Intrathecal Administration: Direct CNS delivery maximizes CNS exposure while reducing peripheral organ exposure
Dose Escalation: Starting with low doses and gradual escalation
Biomarker Monitoring: Tracking target engagement and potential toxicity markers

Considerations for Long-Term Treatment

ALS/FTD are chronic conditions requiring long-term treatment. Long-term considerations include:

Immunogenicity of repeated ASO administration
Potential for off-target effects
CNS tolerance with chronic dosing

Delivery Challenges

Blood-Brain Barrier Penetration

The [blood-brain barrier](/entities/blood-brain-barrier) (BBB) presents a significant challenge for CNS therapeutics. Currently approved ASO therapies for neurological diseases utilize intrathecal (IT) administration to bypass the BBB:

Direct injection into the cerebrospinal fluid
Distribution throughout the CNS via CSF circulation
Achieves therapeutic concentrations in spinal cord and brain tissue

Alternative Delivery Strategies

Research continues on improving CNS delivery:

Conjugated ASOs: ASOs conjugated to ligands that engage transport receptors on the BBB (e.g., transferrin receptor) may enable intravenous delivery

AAV-Vectored ASO Delivery: Using AAV vectors to deliver ASO expression constructs could provide long-lasting ASO production from a single dose

Exosome-Mediated Delivery: Exploring natural extracellular vesicle platforms for CNS-targeted delivery

Distribution Challenges

Even with direct CNS delivery, achieving uniform distribution throughout the brain remains challenging:

Diffusion limited from injection site
Variable penetration into different brain regions
White matter tract distribution considerations

Optimizing Therapeutic Window

The therapeutic window for C9orf72 ASOs involves balancing:

Efficacy: Sufficient target knockdown to reduce toxic species
Safety: Avoiding excessive C9orf72 reduction that may impair normal neuronal function
Sustainability: Maintaining effects over long-term treatment

[C9orf72 Gene](/genes/c9orf72) — The target gene for this therapeutic approach
[ALS-FTD Spectrum](/diseases/als-ftd-spectrum) — The diseases being treated
[TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) — A key pathological hallmark of C9orf72-associated disease
[ASO Brain Delivery](/therapeutics/aso-brain-delivery) — General ASO delivery approaches for CNS diseases
[Gene Editing for Neurodegeneration](/therapeutics/gene-editing-neurodegeneration) — Alternative genetic therapeutic approaches
[RNA Toxicity](/mechanisms/rna-toxicity) — The RNA-mediated disease mechanism

Future Directions

Combination Therapies

ASO monotherapy may ultimately be combined with other therapeutic approaches:

Small molecule inhibitors of DPR aggregation
Neuroprotective agents
Immune modulators
Physical therapy and rehabilitation

Biomarker Development

Robust biomarkers are needed to guide patient selection and treatment response:

CSF DPR levels as pharmacodynamic markers
[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) as disease progression marker
PET tracers for detecting DPR inclusions

Personalized Medicine

Future development may enable genotype-guided therapy:

Stratification based on repeat size
Pharmacogenomic considerations for dose selection

External Links

[ClinicalTrials.gov: C9orf72 ASO trials](https://clinicaltrials.gov/search?cond=C9orf72+ALS)
[ALS Association: C9orf72 Research](https://www.als.org/research/research-news/understanding-c9orf72)
[NIH: C9orf72 Repeat Expansion in ALS/FTD](https://pubmed.ncbi.nlm.nih.gov/23393095/)
[C9orf72 Foundation: Patient Resources](https://www.c9orf72.org/)

References

[Zhang et al., C9orf72 ASO in iPSC models (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30605870/))

[Krach et al., C9orf72 ASO preclinical development (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29953853/))

[Peters et al., C9orf72 repeat translation mechanisms (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25931055/))

[Mori et al., C9orf72 DPR proteins in disease (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23333908/))

[Gendron et al., Antisense oligonucleotides for C9orf72 ALS (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28406235/))

[Jiang et al., C9orf72 ASO in mouse models (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26996078/))

[Donnelly et al., C9orf72 repeat RNA as therapeutic target (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23575164/))

[Lagier-Tourenne et al., Targeted degradation of C9orf72 repeat RNA (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23575160/))

[Zheng et al., C9orf72 ASO clinical trials (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37648571/))

[Unknown, Bristol Myers Squibb C9orf72 ASO program (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35608654/))

[Liu et al., RNase H-mediated ASO mechanism (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/))

[Cheng et al., iPSC motor neuron models for ASO testing (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/))

[Rohrer et al., C9orf72 clinical phenotype (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25533958/))

[Van Blitterswijk et al., C9orf72 genotype-phenotype correlations (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25824008/))

[Baloh et al., C9orf72 ALS/FTD pathophysiology (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/29103959/))

[Unknown, Gitler & Tsuiji, C9orf72 repeat expansion mechanisms (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27545669/))

📖 View canonical wiki page →

Related Entities

therapeutics-aso-c9orf72-als

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-aso-c9orf72-als
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0ebc534e6505
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-aso-c9orf72-als'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

84

Outgoing

86

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD

Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD

Overview

Mechanism of Action

Hexanucleotide Repeat Expansion Pathogenesis

Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD

Overview

Mechanism of Action

Hexanucleotide Repeat Expansion Pathogenesis

ASO Design and Target Selection

Pharmacodynamics

Preclinical Evidence

iPSC Models

Animal Models

Clinical Trials

Biogen/Bristol Myers Squibb ASO Program

Other Programs

Clinical Outcomes

Safety Profile

Observed Adverse Events

Risk Mitigation

Considerations for Long-Term Treatment

Delivery Challenges

Blood-Brain Barrier Penetration

Alternative Delivery Strategies

Distribution Challenges

Optimizing Therapeutic Window

Future Directions

Combination Therapies

Biomarker Development

Personalized Medicine

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD

Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD

Overview

Mechanism of Action

Hexanucleotide Repeat Expansion Pathogenesis

Antisense Oligonucleotide Therapy for C9orf72 ALS/FTD

Overview

Mechanism of Action

Hexanucleotide Repeat Expansion Pathogenesis

ASO Design and Target Selection

Pharmacodynamics

Preclinical Evidence

iPSC Models

Animal Models

Clinical Trials

Biogen/Bristol Myers Squibb ASO Program

Other Programs

Clinical Outcomes

Safety Profile

Observed Adverse Events

Risk Mitigation

Considerations for Long-Term Treatment

Delivery Challenges

Blood-Brain Barrier Penetration

Alternative Delivery Strategies

Distribution Challenges

Optimizing Therapeutic Window

Cross-Linking and Related Pages

Future Directions

Combination Therapies

Biomarker Development

Personalized Medicine

See Also

External Links

References

💬 Discussion